Platform Validation: erythropoietin and hemagglutinin

Successful completion of lab-scale isolation of two additional key therapeutic proteins including erythropoietin and hemagglutinin, through a Shared Research Agreement with Washington University in St. Louis. This achievement further validates the strength and versatility of rBIO’s underlying synthetic biology platform and engineered cellular systems.